Synbiotic Therapy for Kidney Function in CKD Stage III-IV

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a double-blind, randomized, placebo-controlled trial conducted at Chittagong Medical College Hospital in Bangladesh. Approximately 96 adult CKD patients (stage III-IV) not on dialysis will be randomized to receive a synbiotic formulation or placebo for a defined period. The study focuses on the gut-kidney axis, aiming to see if restoring microbial balance reduces inflammation and improves renal function markers. Inclusion criteria require adults with CKD stage III-IV and no recent probiotic use; exclusion criteria include current immunosuppression, bowel diseases, pregnancy, and acute kidney injury. The trial uses a rigorous blinding approach to reduce bias and will analyze renal function outcomes as primary endpoints.

Why it matters

Who can join: the full rules

Inclusion Criteria:

i. Age ≥18 years. ii. Diagnosed chronic kidney disease stage III or IV as per KDIGO guidelines. iii. No use of probiotics, prebiotics, or synbiotics within the previous two weeks.

iv. Willingness to provide written informed consent.

Exclusion Criteria:

i. Current use of immunosuppressive therapy. ii. Presence of chronic diarrhoeal disease, inflammatory bowel disease, or history of major bowel surgery.

iii. Fever or any acute illness within the study period. iv. Pregnancy or lactation. v. Known hypersensitivity to probiotic or synbiotic formulations. vi. Acute kidney injury or requirement for dialysis at the time of screening.

Where it's running

• Chittagong Medical College and Hospital
  Chittagong, Bangladesh Recruiting

Study contacts

• Study coordinator: Md Rezwanul Haque, MBBS
• Email: drrezwanulhaque@gmail.com
• Phone: +8801710457014

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Perirenal SC101 injection to lower blood pressure in resistant hypertension with moderate–severe CKD

  This trial will test whether a single injection of SC101 into the fat around the kidneys can lower blood pressure in adults with resistant hypertension and stage 3–4 chronic kidney disease.

  Recruiting Phase 1 The First Affiliated Hospital with Nanjing Medical University · Suzhou, Jiangsu · NCT07483372

• Herbal Medicine Use in CKD Patients on Réunion Island

  This study tests how common herbal medicine use is among adults with chronic kidney disease (stages 3–5) on Réunion Island and whether it relates to kidney disease progression over a year.

  Recruiting at 4 sites Centre Hospitalier Universitaire de la Réunion · Saint-Benoît and 3 other locations · NCT07444515

• Phosphate assessment in people with chronic kidney disease

  This study will test how increasing dietary phosphate over three weeks affects blood and urine markers in adults with and without stage 3–4 chronic kidney disease.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT07368946

• Equol and vascular function in women with CKD

  This study tests whether taking equol for 12 weeks improves vascular function in postmenopausal women with chronic kidney disease.

  Recruiting Phase 2 University of Colorado, Denver · Aurora, Colorado · NCT07194590

• ACE Reno Pico Cell Matrix for reducing proteinuria and supporting kidney function

  This trial will test whether taking ACE Reno, a sublingual peptide solution four times daily for 12 weeks, can lower urine protein and help stabilize kidney function in adults with nephropathy or chronic kidney disease.

  Recruiting Phase 4 Ace Cells Lab Limited · Giza, GZ · NCT07187713

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.